Additional Resources and Assistance

CareASSIST is here to help you get the information and support you need. In addition to the program offerings, you may also find the following downloads and online resources helpful.

CareASSIST Downloads

CareASSIST Application Download

CareASSIST Application

The CareASSIST application covers all aspects of the program: Access and Reimbursement, Financial Assistance, and Resource Support. Follow the directions on the form to apply, or call 1-833-WE+CARE (1-833-930-2273) to get started.

CareASSIST Brochure Download

CareASSIST Brochure

The CareASSIST brochure contains an overview of the program and its offerings.

CareASSIST Copay Program Overview Brochure Download

CareASSIST Copay Program Overview Brochure

The CareASSIST Copay Program overview brochure describes the program and its requirements.

CareASSIST Resource Navigation Flashcard Download

CareASSIST Resource Navigation Flashcard

An overview of potential sources of prescription assistance.

Online Resources

Certain patients may require information or assistance beyond what CareASSIST may offer. Below are links to external organizations that may be able to help, or you can call 1-833-WE+CARE (1-833-930-2273) to learn about alternate coverage options.

Medicaid.gov

Learn about Medicaid in your state and if you may be eligible.

Medicare.gov

Learn about Medicare and prescription drug coverage, eligibility, and how to access the care you may need.

Patient Advocate Foundation

Find help for insurance and healthcare access problems.

Patient Access Network Foundation

Offers help and hope to people with chronic or life-threatening illnesses for whom cost limits access to breakthrough medical treatments.

American Cancer Society

A nationwide, community-based voluntary health organization dedicated to eliminating cancer as a major health problem.

Cancer Support Community

A global network offering quality cancer support to millions of people touched by cancer, available online and at community-based centers and hospitals.

National Comprehensive Cancer Network®

A not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education.

CancerCare

A leading national organization dedicated to providing free support services and financial assistance to anyone affected by cancer.

INDICATION

ELITEK is indicated for the initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. ELITEK is indicated only for a single course of treatment.

IMPORTANT SAFETY INFORMATION

WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS

  • Hypersensitivity Reactions: ELITEK can cause serious and fatal hypersensitivity reactions including anaphylaxis. Immediately and permanently discontinue ELITEK in patients who experience a serious hypersensitivity reaction.
  • Hemolysis: Do not administer ELITEK to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue ELITEK in patients developing hemolysis. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting ELITEK.
  • Methemoglobinemia: ELITEK can result in methemoglobinemia in some patients. Immediately and permanently discontinue ELITEK in patients developing methemoglobinemia.
  • Interference with Uric Acid Measurements: ELITEK enzymatically degrades uric acid in blood samples left at room temperature. Collect blood samples in pre-chilled tubes containing heparin and immediately immerse and maintain sample in an ice water bath. Assay plasma samples within 4 hours of collection.
  • Among the 347 (265 pediatric; 82 adult) patients for whom all adverse reactions (ARs) regardless of severity were assessed in Studies 1, 2 and 3, as well as an uncontrolled safety trial, the most common ARs (≥10%) were vomiting (50%), fever (46%), nausea (27%), headache (26%), abdominal pain (20%), constipation (20%), diarrhea (20%), mucositis (15%), and rash (13%).
  • Among the 275 adult patients in Study 4, hypersensitivity reactions occurred in 4.3% of patients treated with ELITEK alone and 1.1% of patients treated with the ELITEK plus oral allopurinol. Hypersensitivity reactions included arthralgia, injection site irritation, peripheral edema, and rash. The most common Grade 3-4 ARs regardless of relationship to study drug in Study 4 (ELITEK alone; ELITEK plus oral allopurinol; oral allopurinol alone) were sepsis (5.4%; 6.5%; 4.4%), hypophosphatemia (4.3%; 6.5%; 6.6%), anxiety (3.3%; 0%; 0%), abdominal pain (3.3%; 4.3%; 2.2%), hyperbilirubinemia (3.3%; 2.2%; 4.4%), and increased alanine aminotransferase (3.3%; 4.3%; 2.2%), respectively.
  • The following serious ARs occurred with a difference in incidence of ≥ 2% in patients receiving ELITEK vs. oral allopurinol in Study 1 and Study 4: pulmonary hemorrhage, respiratory failure, supraventricular arrhythmias, ischemic coronary artery disorders, and abdominal and gastrointestinal infections.